Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen

Cumulative incidence of GVHD: acute (A) and chronic (B). Shown separately are the incidences for patients given the prescribed doses of 4.5 or 6.0 mg/kg THY and patients who did not receive the prescribed dose (THY <4.5 mg/kg). The overall incidence of acute GVHD (grades II-IV) was 50%, and the overall incidence of extensive chronic GVHD was 34%.

Reactivation of CMV. Shown is the cumulative incidence of CMV antigenemia in patients conditioned with tBUCY + THY and tBUCY (concurrent controls). Low risk: donor and patient were seronegative; high risk: donor, patient, or both were seropositive.

Chronic GVHD in tBUCY + THY–conditioned patients and in concurrent and historical controls (conditioned with tBUCY). Shown are the cumulative incidences in tBUCY + THY–treated patients who received the prescribed doses of THY (PBPC, THY, 4.5 and 6.0) and tBUCY-conditioned concurrent (PBPC, concurrent) and historical controls (Bone Marrow, historical controls).

Outcome in patients conditioned with tBUCY + THY (this study) and in historical controls conditioned with tBUCY without THY. A, Cumulative incidence of relapse. B, Relapse-free survival.